To assess the impact of genotypic susceptibility score (GSS) on combined antiretroviral therapy (cART) outcomes during primary HIV infection (PHI) we retrospectively enrolled patients with PHI diagnosed between 2008 and 2015 at 9/24 Italian Network ACuTe HIV InfectiON centers. One hundred-seventy-six patients were enrolled. Of these, 55 (32.9%) patients started with more than three drugs and 11 (7.2%) started with a GSS < 3. Regimen's GSS (per 1 point increase) (adjusted odds ratio [aOR], 4.82; 95% confidence interval [CI], 1.62-14.28; P = .005) and baseline HIV-RNA (per 1 log10 increase) (aOR, 2.02; 95% CI, 1.09-3.73; P = .025) resulted associated with early cART initiation. In conclusion, regimen's GSS resulted to be associated to the time to cART initiation during PHI.
Impact of genotypic susceptibility score on cART outcomes during primary HIV infection / Giacomelli, A.; Fabbiani, M.; De Benedetto, I.; Nozza, S.; Foca, E.; Celesia, B. M.; Marchetti, G.; Mussini, C.; Antinori, A.; D'Ettorre, G.; Madeddu, G.; Bandera, A.; Muscatello, A.; Rusconi, S.. - In: JOURNAL OF MEDICAL VIROLOGY. - ISSN 0146-6615. - 91:10(2019), pp. 1891-1895. [10.1002/jmv.25517]
Impact of genotypic susceptibility score on cART outcomes during primary HIV infection
Mussini C.;
2019
Abstract
To assess the impact of genotypic susceptibility score (GSS) on combined antiretroviral therapy (cART) outcomes during primary HIV infection (PHI) we retrospectively enrolled patients with PHI diagnosed between 2008 and 2015 at 9/24 Italian Network ACuTe HIV InfectiON centers. One hundred-seventy-six patients were enrolled. Of these, 55 (32.9%) patients started with more than three drugs and 11 (7.2%) started with a GSS < 3. Regimen's GSS (per 1 point increase) (adjusted odds ratio [aOR], 4.82; 95% confidence interval [CI], 1.62-14.28; P = .005) and baseline HIV-RNA (per 1 log10 increase) (aOR, 2.02; 95% CI, 1.09-3.73; P = .025) resulted associated with early cART initiation. In conclusion, regimen's GSS resulted to be associated to the time to cART initiation during PHI.
| File | Dimensione | Formato | |
|---|---|---|---|
|
jmv.25517.pdf
Accesso riservato
Tipologia:
VOR - Versione pubblicata dall'editore
Dimensione
583.03 kB
Formato
Adobe PDF
|
583.03 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
